<DOC>
	<DOCNO>NCT02865434</DOCNO>
	<brief_summary>Prospective , open-label , multicenter , dose escalation , safety study inject Tc 99m tilmanocept detection assessment localization skeletal joint subject without active RA SPECT imaging .</brief_summary>
	<brief_title>An Evaluation Safety Escalating Doses Tc 99m Tilmanocept Intravenous ( IV ) Injection Skeletal Joint Imaging With SPECT Subjects With Active Rheumatoid Arthritis ( RA ) Healthy Controls</brief_title>
	<detailed_description>Prospective , open-label , multicenter , dose escalation , safety study inject Tc 99m tilmanocept detection assessment localization skeletal joint subject without active RA SPECT image . All subject receive IV administration one 3 mass dos : 50 µg , 200 µg , 400 µg . Within mass dose group , subject receive Tc 99m tilmanocept label one 3 radiolabel dos : 1 mCi , 5 mCi , 10 mCi . All subject whole body planar SPECT scan follow 3D SPECT SPECT/CT scan area interest three specify time point : 30 minute ± 5 minute , 90 minute ± 5 minute 180 minute ± 5 minute .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>ALL SUBJECTS : The subject provide write informed consent HIPAA ( Health Information Portability Accountability Act ) authorization initiation studyrelated procedure . Has negative urine drug screen illicit unprescribed drug suggestive drug abuse . CONTROL SUBJECTS : The subject shall 30 65 year age time consent . The subject deem clinically free inflammatory disease ( ) experience joint pain least 4 week prior consent date . ACTIVE RHEUMATOID ARTHRITIS SUBJECTS : The subject 30 65 year age time consent . The subject moderate severe RA determine 2010 ACR/EULAR ( score ≥ 6/10 ) . The subject DAS28 &gt; 4.4 ( include Erythrocyte Sedimentation Rate [ ESR ] test Visual Analog Scale [ VAS ] ) . If subject receive methotrexate , stable dose &gt; 4 week prior Baseline Visit 2 ( Day 1 ) . If subject receive biologic therapy , stable dose &gt; 8 week prior Baseline Visit 2 ( Day 1 ) . If subject receive NSAIDS oral corticosteroid , dose stable dose &gt; 4 week prior Baseline Visit 2 ( Day 1 ) . The corticosteroid dose ≤ 10mg/day prednisone equivalent steroid dose . The subject pregnant lactating . The subject receive radiopharmaceutical within 7 day prior administration Tc 99m tilmanocept . The subject pregnant lactating . The subject BMI &gt; 34.0 . The subject currently receive radiation therapy chemotherapy condition rheumatoid arthritis . The subject renal insufficiency demonstrate serum creatinine clearance &lt; 60 mL/min . The subject hepatic insufficiency demonstrate ALT AST great two time upper limit normal . The subject chronic persistent infection condition would , opinion examine physician , preclude participation . The subject know allergy adverse reaction dextran exposure . The subject receive investigational product within 30 day prior Tc 99m tilmanocept administration . The subject receive radiopharmaceutical within 7 day prior administration Tc 99m tilmanocept .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>